New HIV Vaccine Strategy Shows Promise in Macaque Study

"The study shows that it is possible, through vaccination, to steer the immune system towards this specific part of the HIV surface protein."
— Gunilla Karlsson Hedestam, Professor at Karolinska Institutet

A vaccine strategy tested in macaques has been shown to induce antibodies capable of neutralizing a wide range of HIV variants. The research involved attaching specially designed HIV proteins to liposomes and administering booster doses with gradually altered proteins.

Study Details and Methodology

Researchers from Karolinska Institutet, The Scripps Research Institute, and Emory University developed the vaccine strategy.

The approach targets the apex of the HIV envelope protein, a conserved region that is often shielded by sugars. The strategy involved attaching multiple copies of a selected HIV surface protein to liposomes, allowing the immune system to be presented with the protein simultaneously.

Macaques were immunized with liposomes linked to the selected protein, then given booster doses in which the protein was gradually altered.

Results

All vaccinated animals developed antibodies that neutralized multiple HIV variants. Analysis of the antibodies showed they bound to the virus's apex in a manner similar to broadly neutralizing antibodies that sometimes develop in humans after long-term HIV infection.

Publication and Funding

The study was published in Nature on April 29, 2026, under the title "Vaccine generates broadly cross-neutralizing antibodies to the HIV Env apex" (DOI: 10.1038/s41586-026-10429-3).

Funding was provided by the US National Institutes of Health. The researchers declared no conflicts of interest.

Future Implications

Gunilla Karlsson Hedestam, professor at Karolinska Institutet and co-senior author, stated that discussions are ongoing regarding potential clinical studies.